Scinai Immunotherapeutics Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Scinai Immunotherapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Scinai Immunotherapeutics Ltd. is an Israeli biopharmaceutical company that operates two distinct business segments: a contract development and manufacturing organization (CDMO) and an in-house research and development unit. The CDMO business unit provides biopharmaceutical development and manufacturing services to external clients. Meanwhile, the R&D segment focuses on advancing biological therapeutics for inflammation and immunology conditions, primarily through a pipeline of nanosized VHH antibody fragments. Its therapeutic development efforts include targeting Interleukin-17 for autoimmune diseases such as plaque psoriasis and psoriatic arthritis, as well as an optioned monoclonal antibody candidate targeting soluble Fas ligand.
The company operates manufacturing and development facilities in Jerusalem and Yavne, Israel. Its principal executive offices and corporate headquarters are located at the Jerusalem BioPark on the Hadassah Ein Kerem Campus in Jerusalem, Israel. Additionally, the company conducts activities internationally through a wholly owned subsidiary in Poland.
Summary of the business section of Scinai Immunotherapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Scinai Immunotherapeutics Ltd.
- Headquarters
- Jerusalem, L3
- Address
- Jerusalem Biopark, 2nd Floor, Hadassah Ein Kerem Campus 00000
- Phone
- 972-8-9302529
- Employees
- 45, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Ziv Haft, Tel-Aviv,Israel
Stock & identifiers
- Ticker
- SCNI
- Exchange
- Nasdaq
- IPO date
- May 13, 2015
- Shares outstanding
- 13.87B, Dec 31, 2025
- Public float
- $16.70M, Jun 30, 2022
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-10 reverse, Aug 21, 2026; 1-for-10 reverse, May 21, 2024; 1-for-10 reverse, Nov 25, 2022
- SEC CIK
- 1611747
- CUSIP
- 09073Q203
- ISIN
- US09073Q2031
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Amir Reichman | Chief Executive Officer, Director | 711,637,600 |
| Elad Mark | Chief Operating Officer | 160,355,016 |
| Mark Germain | Director | 120,000,000 |
| Yael Margolin | Director | 66,800 |
| Uri Ben-Or | Director | 33,329,004 |
| Samuel J. Moed | Director | – |
| Adi Raviv | Director | 66,800 |
| Jay Green | Director | – |
Employees
Headcount reported in annual reports
“45 employees, 41 of whom were employed in the CDMO subsidiary company and 4 of whom were employed in research and development.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 29, 2025 | Late filing | Notification of late filing |
| Apr 30, 2024 | Late filing | Notification of late filing |
| Aug 28, 2023 | Name change | Name changed from BiondVax Pharmaceuticals Ltd. to Scinai Immunotherapeutics Ltd. |
| May 4, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 3, 2023 | Late filing | Notification of late filing |
| Apr 29, 2021 | Late filing | Notification of late filing |
| May 13, 2020 | Delisting | Notice of delisting from exchange (Form 25) |
| May 13, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 20, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |